Volume 25, Issue 12, Pages e3 (December 2018)

Slides:



Advertisements
Similar presentations
The Role of Heterotypic DENV-specific CD8+T Lymphocytes in an Immunocompetent Mouse Model of Secondary Dengue Virus Infection  Laura B. Talarico, Juan.
Advertisements

In Vivo Production of Monoclonal Antibodies by Gene Transfer via Electroporation Protects against Lethal Influenza and Ebola Infections  Chasity D. Andrews,
CD154 Expression Is Associated with Neutralizing Antibody Titer Levels Postinfluenza Vaccination in Stem Cell Transplant Patients and Healthy Adults 
Pathways Responsible for Human Autoantibody and Therapeutic Intravenous IgG Activity in Humanized Mice  Inessa Schwab, Anja Lux, Falk Nimmerjahn  Cell.
Allergy prevention starts before conception: Maternofetal transfer of tolerance protects against the development of asthma  Tobias Polte, PhD, Christian.
Volume 25, Issue 6, Pages (June 2017)
Volume 16, Issue 5, Pages (August 2016)
Volume 22, Issue 7, Pages (February 2018)
Volume 41, Issue 4, Pages (October 2014)
Enteric helminth-induced type I interferon signaling protects against pulmonary virus infection through interaction with the microbiota  Amanda J. McFarlane,
Volume 23, Issue 6, Pages (May 2018)
Jennifer R. Hamilton, Gayathri Vijayakumar, Peter Palese  Cell Reports 
Volume 14, Issue 4, Pages (February 2016)
Volume 170, Issue 2, Pages e12 (July 2017)
Volume 22, Issue 4, Pages e4 (October 2017)
Volume 18, Issue 1, Pages (July 2015)
Treatment of SFTSV-infected IFNAR−/− mice with T-705 or ribavirin.
Fig. 1 ZIKV-related flaviviruses cause fetal demise in mice that can be prevented by mAb treatment. ZIKV-related flaviviruses cause fetal demise in mice.
Prevention of Genital Herpes Simplex Virus Type 1 and 2 Disease in Mice Immunized with a gD-Expressing Dominant-Negative Recombinant HSV-1  Richard Brans,
Volume 21, Issue 7, Pages (November 2017)
Volume 16, Issue 12, Pages (September 2016)
Volume 167, Issue 3, Pages e9 (October 2016)
Volume 3, Issue 4, Pages (April 2013)
Volume 6, Issue 4, Pages (October 2009)
Brian Yordy, Norifumi Iijima, Anita Huttner, David Leib, Akiko Iwasaki 
Volume 36, Issue 3, Pages (March 2012)
Gestational Stage and IFN-λ Signaling Regulate ZIKV Infection In Utero
Volume 13, Issue 11, Pages (December 2015)
Volume 26, Issue 2, Pages (February 2018)
Volume 19, Issue 1, Pages (January 2016)
Volume 42, Issue 4, Pages (April 2015)
Volume 22, Issue 12, Pages (March 2018)
A Mouse Model of Zika Virus Pathogenesis
Endogenous polyclonal anti–IL-1 antibody responses potentiate IL-1 activity during pathogenic inflammation  Gunther Spohn, PhD, Natalia Arenas-Ramirez,
Volume 2, Issue 6, Pages (December 2007)
Volume 44, Issue 3, Pages (March 2016)
TAM Receptors Are Not Required for Zika Virus Infection in Mice
Volume 19, Issue 2, Pages (February 2016)
Hemagglutinin-targeting Artificial MicroRNAs Expressed by Adenovirus Protect Mice From Different Clades of H5N1 Infection  Xinying Tang, Hongbo Zhang,
Volume 21, Issue 6, Pages (November 2017)
Modified mRNA Vaccines Protect against Zika Virus Infection
Volume 18, Issue 2, Pages (January 2017)
Volume 16, Issue 6, Pages (August 2016)
In Vivo Production of Monoclonal Antibodies by Gene Transfer via Electroporation Protects against Lethal Influenza and Ebola Infections  Chasity D. Andrews,
Volume 25, Issue 9, Pages (September 2017)
Volume 25, Issue 4, Pages (April 2017)
Volume 17, Issue 12, Pages (December 2016)
Matthew Charles Woodruff, Eui Ho Kim, Wei Luo, Bali Pulendran 
Katelyn T. Byrne, Robert H. Vonderheide  Cell Reports 
Volume 22, Issue 5, Pages e5 (November 2017)
Volume 16, Issue 5, Pages (August 2016)
Volume 166, Issue 5, Pages e4 (August 2016)
Volume 22, Issue 5, Pages e5 (November 2017)
Lukxmi Balathasan, Vera A
Volume 19, Issue 9, Pages (May 2017)
Katelyn T. Byrne, Robert H. Vonderheide  Cell Reports 
Volume 21, Issue 1, Pages (January 2017)
Volume 26, Issue 7, Pages e4 (February 2019)
Volume 24, Issue 7, Pages (August 2018)
Volume 22, Issue 4, Pages e5 (October 2017)
Volume 26, Issue 6, Pages e4 (February 2019)
Volume 25, Issue 12, Pages e5 (December 2018)
Volume 26, Issue 4, Pages (April 2018)
Volume 166, Issue 5, Pages e4 (August 2016)
Volume 20, Issue 4, Pages (April 2012)
Volume 26, Issue 11, Pages e4 (March 2019)
Intestinal Epithelial Cell Autophagy Is Required to Protect against TNF-Induced Apoptosis during Chronic Colitis in Mice  Johanna Pott, Agnieszka Martyna.
Volume 23, Issue 6, Pages (May 2018)
Volume 23, Issue 12, Pages (June 2018)
UV Exposure Boosts Transcutaneous Immunization and Improves Tumor Immunity: Cytotoxic T-Cell Priming through the Skin  Pamela Stein, Gerd Rechtsteiner,
Presentation transcript:

Volume 25, Issue 12, Pages 3382-3392.e3 (December 2018) An mRNA Vaccine Protects Mice against Multiple Tick-Transmitted Flavivirus Infections  Laura A. VanBlargan, Sunny Himansu, Bryant M. Foreman, Gregory D. Ebel, Theodore C. Pierson, Michael S. Diamond  Cell Reports  Volume 25, Issue 12, Pages 3382-3392.e3 (December 2018) DOI: 10.1016/j.celrep.2018.11.082 Copyright © 2018 The Author(s) Terms and Conditions

Cell Reports 2018 25, 3382-3392.e3DOI: (10.1016/j.celrep.2018.11.082) Copyright © 2018 The Author(s) Terms and Conditions

Figure 1 Lineage I and II POWV Strains Cause Lethal Disease in Adult Mice (A–C) C57BL/6 mice were inoculated via subcutaneous inoculation in the footpad with 102 FFU of POWV lineage I LB at 7 weeks (n = 14) or 14 weeks (n = 15) of age. Mice were monitored for (A) mortality, (B) weight loss, and (C) clinical disease for 21 days. (D–F) C57BL/6 mice were inoculated subcutaneously at 7 weeks (n = 14) or 14 weeks (n = 10) of age with 102 FFU of POWV Spooner or at 14 weeks of age after treatment with 0.5 mg of anti-Ifnar1 mAb administered via intraperitoneal one day before inoculation with POWV lineage II Spooner (n = 15). Mice were monitored for (D) mortality, (E) weight change, and (F) clinical disease for 21 days. (B and E) Error bars represent SEM. Data were collected from two (Spooner infection of 7-week-old mice) or three (all other data) independent experiments. Cell Reports 2018 25, 3382-3392.e3DOI: (10.1016/j.celrep.2018.11.082) Copyright © 2018 The Author(s) Terms and Conditions

Figure 2 POWV mRNA LNP Vaccine Induces High Levels of Neutralizing Antibody in Mice (A) Scheme of the two-dose POWV Spooner mRNA LNP vaccination schedule. (B–H) Serum samples collected pre- and post-boost were assayed for neutralization potency by an RVP-based assay using a lineage II POWV strain (P0375) and Raji-SIGNR cells (n = 20 for JEVsig and placebo; n = 19 for POWVsig). (B) The reciprocal neutralization titers (EC50 values) are shown. Bars represent median values. Statistical significance was determined using an ANOVA followed by Tukey’s multiple comparisons test (ns, not significant; ∗p < 0.05; ∗∗∗∗p < 0.0001). (C–H) Representative dose response curves are shown for each vaccine and time point. The mean resistant fraction (RF) ± SEM is indicated on each panel. Error bars represent ± SEM from two technical replicates. Serum samples were collected over four independent experiments and assayed once each for neutralization potency. See also Figure S1. Cell Reports 2018 25, 3382-3392.e3DOI: (10.1016/j.celrep.2018.11.082) Copyright © 2018 The Author(s) Terms and Conditions

Figure 3 POWV mRNA LNP Vaccines Induce Protective Immunity against Lineage I and II POWV Strains (A–F) C57BL/6 mice receiving two doses of POWVsig or JEVsig vaccines or a placebo were challenged 4 weeks after the second dose with 102 FFU of (A–C) POWV lineage II strain Spooner (following anti-Ifnar1 mAb treatment) (n = 10 per group) or (D–F) POWV lineage I strain LB (n = 10 for JEVsig and placebo; n = 9 for POWVsig). (G–I) Serum samples were collected from mice that received two doses of POWVsig or a placebo and passively transferred to naive C57BL/6 mice one day before challenge with 102 FFU POWV LB (n = 9 per group). Mice received a dose of 3 or 10 μL of vaccine immune serum or 10 μL of placebo serum. Mice were monitored for mortality (A, D, and G) for 21 days following viral challenge. Statistical significance was determined by the log rank test with a Bonferroni correction (∗∗∗p < 0.001; ∗∗∗∗p < 0.0001). Mean weight change (B, E, and H) post-viral challenge is shown. Error bars represent SEM. Statistical significance was determined using an ANOVA with Dunnett’s multiple comparisons test to compare vaccine groups to the placebo group (ns, not significant; ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001). Serum was collected at 2 dpi and measured for viremia (C, F, and I) by qRT-PCR. Bars indicate median values. Statistical significance was determined using the Kruskal-Wallis test with Dunn’s multiple comparisons test to compare vaccine groups to the placebo group (∗p < 0.05; ∗∗∗∗p < 0.0001). Data in each panel were collected over two independent experiments; n = 9–10 mice per group. Cell Reports 2018 25, 3382-3392.e3DOI: (10.1016/j.celrep.2018.11.082) Copyright © 2018 The Author(s) Terms and Conditions

Figure 4 Single Dose of an mRNA LNP Vaccine Induces Protective Immunity against POWV Challenge C57BL/6 mice receiving one dose of the POWVsig mRNA vaccine or a placebo vaccine were challenged 29 days later with 102 FFU of POWV Spooner (following anti-Ifnar1 mAb treatment) (n = 10 per group). (A) Mice were monitored for mortality for 21 days after viral challenge. Statistical significance was determined by log rank test (∗∗∗∗p < 0.0001). (B) Mean weight change after virus challenge is shown. Error bars represent SEM. Statistical significance was determined using an ANOVA with Sidak’s multiple comparisons test (∗∗∗∗p < 0.0001). (C) Serum was collected at 2 dpi and measured for viremia by qRT-PCR. Median viral titers are shown. Statistical significance was determined by Mann-Whitney test (∗∗∗∗p < 0.0001). (D–F) Serum was collected at 2 and 21 days post-challenge and assayed for neutralization activity by RVP assay. (D) Neutralization titers are shown. Bars indicate median values. Statistical significance was determined by paired t test. (E and F) Representative dose response curves are shown of sera collective at day 2 (E) and day 21 (F) post-challenge. Error bars represent ± SEM from two technical replicates. Serum samples were collected over two independent experiments and assayed once each for neutralization potency. Cell Reports 2018 25, 3382-3392.e3DOI: (10.1016/j.celrep.2018.11.082) Copyright © 2018 The Author(s) Terms and Conditions

Figure 5 POWV mRNA Vaccine Induces Cross-Neutralizing Antibodies against Other Tick-Borne Flaviviruses (A) Dendrogram depicting the relatedness of tick-borne flavivirus E proteins (scale bar represents 0.2 amino acid substitutions per site). (B–D) Serum samples collected post-boost in Figure 2 were evaluated by RVP assay for neutralizing activity against (B) TBEV (POWVsig and JEVsig, n = 15; placebo, n = 8), (C) LGTV (POWVsig and JEVsig, n = 13; placebo, n = 7), and (D) GGYV (POWVsig and JEVsig, n = 15; placebo, n = 8). Median EC50 values are shown. Statistical significance was determined using an ANOVA with Dunnett’s multiple comparisons test to compare vaccine and placebo group (ns, not significant; ∗p < 0.05; ∗∗p < 0.01; ∗∗∗∗p < 0.0001). Serum samples were collected over four independent experiments and assayed once for neutralization potency. See also Figures S1 and S2. Cell Reports 2018 25, 3382-3392.e3DOI: (10.1016/j.celrep.2018.11.082) Copyright © 2018 The Author(s) Terms and Conditions

Figure 6 POWV mRNA Vaccine Cross-Protects against LGTV Challenge C57BL/6 mice receiving two doses of the POWVsig (n = 15) or placebo (n = 15) vaccines were challenged 4 weeks after boosting with 102 FFU of LGTV (one day post-anti-Ifnar1 mAb treatment, 0.5 mg). (A) Mice were monitored for weight change for 15 days following viral challenge. Mean weight change is shown. Error bars represent SEM. Statistical significance was determined using an ANOVA with Sidak’s multiple comparisons test (∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001). (B) Mice were scored for signs of paralysis following viral challenge. (C) Serum was collected at 2 dpi and measured for viremia by qRT-PCR. (D) At day 15 post-viral challenge, the indicated tissues were harvested, and viral load was determined by qRT-PCR. (C and D) Median viral titers are shown. Statistical significance was determined by Mann-Whitney test (∗∗∗∗p < 0.0001). Data are from three independent experiments. Cell Reports 2018 25, 3382-3392.e3DOI: (10.1016/j.celrep.2018.11.082) Copyright © 2018 The Author(s) Terms and Conditions